Camp4 Therapeutics (CAMP) CSO sells ESPP shares

Rhea-AI Filing Summary

Camp4 Therapeutics Corp (CAMP) reported an insider sale by Chief Scientific Officer Daniel Tardiff. On August 19, 2026, he sold 1,738 shares of common stock in a sale characterized as an open market or private transaction at $4.76 per share. Following this transaction, his reported direct holdings of common stock from this lot were 0 shares. The shares had been previously acquired through the company’s Employee Stock Purchase Plan for the purchase period from January 1, 2026 through June 30, 2026 in a transaction described as exempt under Rule 16b-3(c).

Insider Trade Summary

Net Seller: 1,738 shares

Net Sell 1 txn

Insider Tardiff Daniel

Role Chief Scientific Officer

Sold 1,738 shs ($8K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	1,738	$4.76	$8K

Holdings After Transaction: Common Stock — 0 shares (Direct)

Footnotes (1)

1. F1. The shares sold were previously acquired by the reporting person pursuant to the CAMP4 Therapeutics Corporation Employee Stock Purchase Plan (the "ESPP") for the purchase period of January 1, 2026 through June 30, 2026 in a transaction that was exempt under Rule 16b-3(c).

Key Figures

Shares sold: 1,738 shares Sale price per share: $4.76 per share Shares held after transaction: 0 shares +2 more

5 metrics

Shares sold 1,738 shares Common stock sale by Chief Scientific Officer Daniel Tardiff on August 19, 2026

Sale price per share $4.76 per share Price for the 1,738 CAMP common shares sold on August 19, 2026

Shares held after transaction 0 shares Total shares following transaction for this reported holding

ESPP purchase period start January 1, 2026 Beginning of Employee Stock Purchase Plan period for the shares sold

ESPP purchase period end June 30, 2026 End of Employee Stock Purchase Plan period for the shares sold

Key Terms

Employee Stock Purchase Plan, Rule 16b-3(c), open market or private transaction

3 terms

Employee Stock Purchase Plan financial

"The shares sold were previously acquired by the reporting person pursuant to the CAMP4 Therapeutics Corporation Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Rule 16b-3(c) regulatory

"in a transaction that was exempt under Rule 16b-3(c)"

An SEC rule that lets corporate insiders avoid automatic "short‑swing" profit recovery when they buy or sell their company’s stock under a pre‑approved, written plan that meets specific conditions. For investors, it matters because it clarifies when insider trades are treated as routine, reducing legal uncertainty and helping distinguish trades made for ordinary compensation or pre‑planned reasons from those that might signal opportunistic or timely insider advantage.

open market or private transaction financial

"transaction_code_description: Sale in open market or private transaction"

FAQ

What insider transaction did CAMP report for Chief Scientific Officer Daniel Tardiff?

Camp4 Therapeutics reported that Chief Scientific Officer Daniel Tardiff sold 1,738 shares of common stock on August 19, 2026 at $4.76 per share. The sale was recorded as an open market or private transaction.

How many CAMP shares did Daniel Tardiff sell and at what price?

Daniel Tardiff sold 1,738 CAMP shares at a price of $4.76 per share on August 19, 2026. This transaction was reported as a sale of common stock in a Form 4 filing.

What are Daniel Tardiff’s reported CAMP holdings after this Form 4 transaction?

After the reported transaction, Daniel Tardiff’s direct holdings from this lot were listed as 0 shares of Camp4 Therapeutics common stock. The Form 4 states a total shares following transaction value of zero for this position.

How were the CAMP shares sold by Daniel Tardiff originally acquired?

The 1,738 Camp4 Therapeutics shares sold by Daniel Tardiff were originally acquired through the company’s Employee Stock Purchase Plan for the purchase period from January 1, 2026 to June 30, 2026, according to the filing footnote.

Was Daniel Tardiff’s CAMP share acquisition or sale linked to Rule 16b-3(c)?

Yes. The acquisition of the shares through the Employee Stock Purchase Plan for the January 1–June 30, 2026 period is described as exempt under Rule 16b-3(c). The Form 4 footnote specifies this exemption for that ESPP transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/19/2026 - 08:46 PM Accepted by SEC EDGAR 08/19/2026 - 08:46 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tardiff Daniel

(Last) (First) (Middle)

C/O CAMP4 THERAPEUTICS CORPORATION

100 TALCOTT AVENUE, SUITE 201

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Camp4 Therapeutics Corp [ CAMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2026		S		1,738(1)	D	$4.76	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares sold were previously acquired by the reporting person pursuant to the CAMP4 Therapeutics Corporation Employee Stock Purchase Plan (the "ESPP") for the purchase period of January 1, 2026 through June 30, 2026 in a transaction that was exempt under Rule 16b-3(c).

Remarks:

	/s/ Daniel Tardiff	08/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)